Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Praxis Precision Medicines, Inc. surged 35% after EMBOLD study success and strong pipeline progress, reaching its highest valuation since early 2022. PRAX's relutrigine and ulixacaltamide both ...
Having already claimed a win for the phase 2 study of its seizure drug, Praxis Precision Medicines is hoping fresh efficacy data will form the backbone of an approval application for the sodium ...
Investing.com -- Praxis Precision Medicines (NASDAQ:PRAX) stock surged 25% after the company announced its EMBOLD study evaluating relutrigine was stopped early due to positive efficacy results. The ...
BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
remove-circle Internet Archive's in-browser bookreader "theater" requires JavaScript to be enabled. It appears your browser does not have it turned on. Please see ...
This programme is only open to applicants who qualify for Home fees. If you are unsure whether you are classed as a Home or Overseas student, or you are an EU student, visit the University's fee ...
Praxis Precision Medicines, Inc. is upgraded to a Strong Buy, driven by pipeline progress and positive phase 3 data for Ulixacaltamide in Essential Tremor. PRAX's Ulixacaltamide achieved primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback